IP Library Granted Patent US 10,537,530
Granted Patent B2
US 10,537,530 · App. 13/603,984 · Granted Jan 21, 2020

Solid dosage forms comprising an enteric coating with accelerated drug release

Inventors: Fang Liu (London, GB); Abdul W. Basit (Harrow Middlesex, GB); Rosario Lizio (Dieburg, DE); Hans-Ulrich Petereit (Darmstadt, DE); Christian Meier (Darmstadt, DE); Michael Damm (Roedermark, DE)
Assignee: Evonik Operations GmbH
A61K9/5073A61K9/5026
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,537,530
App. No.
13/603,984
Granted
Jan 21, 2020
Kind
B2
Abstract

The invention provides a gastric resistant, enteric-coated solid dosage form including a core containing a pharmaceutically active ingredient, an inner coating for the core, and an outer enteric coating. The inner coating comprises an anionic polymeric material or a water-soluble neutral polymeric material, and further comprises a water soluble inorganic salt which is not a carbonate or bicarbonates. The outer enteric coating comprises an anionic polymeric material which is less neutralized than the polymeric material comprising the inner coating and disintegrates rapidly at a pH of 5.5 to 7.0 upon entering the small intestine.

Claims (16)

1. A gastric resistant, enteric-coated solid dosage form comprising

an inner coating located between a core containing a pharmaceutically active ingredient and an outer enteric coating;

wherein said inner coating further comprises at least one water soluble inorganic salt, wherein the cation of the inorganic salt is selected from the group consisting of alkali metal, alkaline earth metal, ammonium, manganese, iron, copper, zinc, and molybdenum cations, and the anion of the inorganic salt is selected from the group consisting of chloride, fluoride, bromide, iodide, nitrate, nitrite, and sulphate anions, with the proviso that carbonates and bicarbonates are excluded; and

wherein each of the outer and the inner coatings comprises a partially neutralized anionic (meth)acrylate copolymer consisting of free-radical polymerized units of 25 to 95% by weight C1- to C4-alkyl esters of acrylic or of methacrylic acid and 5 to 75% by weight (meth)acrylate monomers having an anionic group, wherein the outer coating is less neutralized than the inner coating.

2. A gastric resistant, enteric-coated solid dosage form comprising

an inner coating located between a core containing a pharmaceutically active ingredient and an outer enteric coating;

wherein said inner coating further comprises at least one water soluble inorganic salt, wherein the cation of the inorganic salt is selected from the group consisting of alkali metal, alkaline earth metal, ammonium, manganese, iron, copper, zinc, and molybdenum cations, and the anion of the inorganic salt is selected from the group consisting of chloride, fluoride, bromide, iodide, nitrate, nitrite, and sulphate anions, with the proviso that carbonates and bicarbonates are excluded; and

wherein the inner coating comprises a partially neutralized anionic (meth)acrylate copolymeric material and the outer coating comprises the same partially neutralized anionic (meth)acrylate copolymeric material of the inner coating, with the proviso that the partially neutralized anionic (meth)acrylate copolymeric material of the outer coating is less neutralized than the partially neutralized anionic (meth)acrylate copolymeric material of the inner coating.

3. A gastric resistant, enteric-coated solid dosage form comprising

an inner coating located between a core containing a pharmaceutically active ingredient and an outer enteric coating;

wherein said inner coating further comprises at least one water soluble inorganic salt, wherein the cation of the inorganic salt is selected from the group consisting of alkali metal, alkaline earth metal, ammonium, manganese, iron, copper, zinc, and molybdenum cations, and the anion of the inorganic salt is selected from the group consisting of chloride, fluoride, bromide, iodide, nitrate, nitrite, and sulphate anions, with the proviso that carbonates and bicarbonates are excluded; and

wherein each of the outer and the inner coating comprises a partially neutralized anionic (meth)acrylate copolymer consisting of free-radical polymerized units of 25 to 95% by weight C1- to C4-alkyl esters of acrylic or of methacrylic acid and 5 to 75% by weight (meth)acrylate monomers having an anionic group, wherein the outer coating is less neutralized than the inner coating.

4. A gastric resistant, enteric-coated solid dosage form comprising

an inner coating located between a core containing a pharmaceutically active ingredient and an outer enteric coating;

wherein said inner coating further comprises at least one water soluble inorganic salt, wherein the cation of the inorganic salt is selected from the group consisting of alkali metal, alkaline earth metal, ammonium, manganese, iron, copper, zinc, and molybdenum cations, and the anion of the inorganic salt is selected from the group consisting of chloride, fluoride, bromide, iodide, nitrate, nitrite, and sulphate anions, with the proviso that carbonates and bicarbonates are excluded; and

wherein the inner coating comprises a partially neutralized anionic (meth)acrylate copolymeric material and the outer coating consists essentially of the same partially neutralized anionic (meth)acrylate copolymeric material of the inner coating, with the proviso that the partially neutralized anionic (meth)acrylate copolymeric material of the outer coating is less neutralized than the partially neutralized anionic (meth)acrylate copolymeric material of the inner coating.

Assignments (3)
CHANGE OF NAME Recorded Nov 18, 2019
From: EVONIK RÖHM GMBH
To: RÖHM GMBH
Reel/Frame 051038/0309 →
CHANGE OF NAME Recorded Nov 18, 2019
From: EVONIK DEGUSSA GMBH
To: EVONIK OPERATIONS GMBH
Reel/Frame 051038/0471 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2019
From: RÖHM GMBH
To: EVONIK DEGUSSA GMBH
Reel/Frame 051046/0035 →